Verbatim response from ChatGPT
Short answer
- Many people start to see meaningful weight loss within weeks and lose the most during the first 3–6 months. How fast depends on which GLP‑1 or GLP‑1/GIP drug, dose, starting weight and whether you combine it with lifestyle changes.
- Typical trial results (averages): semaglutide 2.4 mg (Wegovy) → ~10–15% body‑weight loss at ~68 weeks; tirzepatide (Zepbound/Mounjaro) → larger averages in trials (roughly mid‑teens to low‑twenties percent at ~72 weeks). Individual results vary widely.
More detail
- Timeline: early appetite suppression and nausea often cause relatively quick losses in the first 1–3 months. Weight loss generally continues but slows after 6–12 months and often reaches a new plateau by ~9–18 months.
- Amount: in clinical trials, most people did better than usual diet-alone results: many lost 5–10% body weight in the first few months and more over the first year (see above trial averages). A minority lose much larger amounts; some lose less or not at all.
- Variability: starting BMI, dose (higher doses produce more weight loss in trials), adherence, diet/exercise, metabolic differences, and side effects all affect how fast and how much you lose.
Is it sustainable?
- If you stay on the medication and use ongoing lifestyle changes, many people maintain a large portion of the loss. Trials show continued benefit while medication is continued.
- Stopping the drug commonly leads to partial or full weight regain over months to a year in many people because the underlying biological drivers of appetite and energy expenditure reassert themselves.
- For long‑term maintenance you usually need one or more of: ongoing medication, durable lifestyle/behavior changes, structured support (dietitian/therapy/exercise), or in some cases bariatric surgery. Talk with your clinician about realistic long‑term plans.
Safety, monitoring and practical points
- Expect GI side effects (nausea, diarrhea, constipation) that usually lessen with slow dose titration.
- Important to have medical follow‑up: baseline labs, monitoring for glucose changes (if diabetic), interactions with other drugs, and screening for contraindications (personal/family history of medullary thyroid cancer or MEN2, pregnancy).
- Cost and insurance coverage vary; branded weight‑loss formulations can be expensive.
Brands and services to consider
- Wegovy (semaglutide, Novo Nordisk) — FDA‑approved for chronic weight management; good evidence from STEP trials for meaningful weight loss.
- Zepbound (tirzepatide, Eli Lilly) — the tirzepatide molecule showed some of the largest average weight losses in clinical trials (SURMOUNT), and Zepbound is approved for weight management in many places.
- Ozempic (semaglutide, Novo Nordisk) and Mounjaro (tirzepatide, Eli Lilly) are approved for diabetes and are sometimes used off‑label for weight loss; dosing and outcomes differ from the dedicated weight‑loss formulations.
- For care: seek a prescriber with experience using GLP‑1s for obesity — endocrinologists, bariatric medicine specialists, or multidisciplinary weight‑management clinics. Telemedicine companies (many local options exist) can help with access, but choose one that provides medical monitoring, dietitian support and long‑term follow‑up.
What to do next
- Talk with your primary care clinician, endocrinologist or a weight‑management clinic to review whether a GLP‑1/GIP drug is appropriate for you, discuss risks/benefits, and design a plan for medication, lifestyle change and long‑term follow up.
If you want, tell me your starting weight, height, medical history and whether you have diabetes or other meds — I can give a more personalized expectation and next steps.